TABLE 1

Clinical Data on 27 Patients with Endocrine Neoplasms Evaluated by TET

Patient no.	Sex	Age (y)	Diagnosis	Radiopharmaceutical	Reason for test
1	M	44	Gastrinoma	¹¹¹In-octreotide	Suspected recurrence, elevated gastrin levels, normal CT
2	M	41	Recurrent nonsecreting NE tumor	¹¹¹In-octreotide	Retroperitoneal mass on CT, resectability assessment
3	F	58	Nonsecreting NE tumor	¹¹¹In-octreotide	Pancreatic mass on CT, resectability assessment
4	F	57	Metastatic carcinoid	¹¹¹In-octreotide	Known liver metastases, extent of disease, treatment planning
5	M	47	Metastatic carcinoid	¹¹¹In-octreotide	Known liver metastases, extent of disease, treatment planning
6	M	60	Metastatic carcinoid	¹¹¹In-octreotide	Known liver metastases, suspected lesion R lower lung on CT, extent of disease, treatment planning
7	M	40	Medullary thyroid carcinoma	¹¹¹In-octreotide	Mediastinal mass on CT, treatment planning
8	M	36	Medullary thyroid carcinoma	¹¹¹In-octreotide	Suspected recurrence, elevated calcitonin levels, normal CT
9	F	53	Suspected gastrinoma (excluded)	¹¹¹In-octreotide	Elevated gastrin levels, normal CT
10	M	31	Suspected insulinoma (excluded)	¹¹¹In-octreotide	Hypoglycemia, suspected pancreatic mass on CT
11	M	70	Parathyroid adenoma	^99mTc-sestamibi	Diagnosis and localization
12	M	28	Parathyroid adenoma	^99mTc-sestamibi	Diagnosis and localization
13	F	48	Parathyroid adenoma	^99mTc-sestamibi	Diagnosis and localization
14	F	81	Parathyroid (ectopic) adenoma	^99mTc-sestamibi	Localization of adenoma before surgery
15	F	70	Parathyroid (ectopic) adenoma	^99mTc-sestamibi	Localization of adenoma before surgery
16	F	54	Suspected parathyroid adenoma (excluded)	^99mTc-sestamibi	Diagnosis
17	F	65	Suspected parathyroid adenoma (excluded)	^99mTc-sestamibi	Diagnosis
18	M	48	Suspected parathyroid adenoma (excluded)	^99mTc-sestamibi	Diagnosis
19	M	46	Papillary thyroid carcinoma	¹³¹I	Known lung metastases, extent of disease, treatment planning
20	M	77	Papillary thyroid carcinoma	¹³¹I	Known lung metastases, extent of disease, treatment planning
21	F	68	Papillary thyroid carcinoma	¹³¹I	Lung metastases, state after radioiodine treatment, evaluation of residual disease
22	M	68	Follicular thyroid carcinoma	¹³¹I	Lung and bone metastases, extent of disease
23	F	68	Suspected pheochromocytoma (excluded)	¹²³I-MIBG	Hypertension (suspected secondary), normal CT
24	F	48	Suspected pheochromocytoma	¹²³I-MIBG	Elevated catecholamines, suspected R adrenal mass on CT
25	M	5	Neuroblastoma	¹²³I-MIBG	Residual mass on CT, monitoring response to treatment
26	M	59	Suspected aldosteronoma	⁷⁵Se-cholesterol	Bilateral mild adrenal enlargement on CT
27	F	40	Suspected aldosteronoma (excluded)	⁷⁵Se-cholesterol	Adrenal mass on CT

CT = high-resolution, contrast-enhanced conventional CT; NE = neuroendocrine.